

January 7, 2020

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2017-002292-26 / Novartis Protocol ID CLYS228X2201

A randomized, controlled, evaluator-blinded, multicenter, study to evaluate LYS228 pharmacokinetics, clinical response, safety and tolerability in patients with complicated urinary tract infection

Trial CLYS228X2201 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.

